Evidence map›Paper›PMID 34874517›Full record

ArticleChinese journal of integrative medicine2022

Effect of Shenmai Injection on Long-Term Prognosis of Patients with Chronic Heart Failure: A Multicenter, Large Sample Capacity, Long-Term Follow-Up Retrospective Cohort Study.

Hui Guan, Guo-Hua Dai, Wu-Lin Gao, Tong Zhang, Cong Sun, Li-Li Ren, Xiao-Ming Hou, Zhang Liu

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Chinese journal of integrative medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hui GuanThe First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, 250014, China.
Guo-Hua DaiAffiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, China. daigh2004@163.com.
Wu-Lin GaoAffiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, China.
Tong ZhangAffiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, China.
Cong SunThe First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, 250014, China.
Li-Li RenThe First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, 250014, China.
Xiao-Ming HouThe First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, 250014, China.
Zhang LiuThe First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, 250014, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the effect of Shenmai Injection (SMI) on the long-term prognosis of patients with chronic heart failure (CHF).

methodsThe Hospital Information System was used to extract data of CHF patients, and the retrospective cohort study was conducted for analysis. In non-exposed group, standardized Western medicine treatment and Chinese patent medicine or decoction were applied without combination of SMI while in the exposed group, SMI were applied for more than 7 days. Evaluation indicators are followed with New York Heart Association functional classification (NYHA classification), left ventricular ejection fraction (LVEF), N-terminal brain natriuretic peptide precursor (NT-ProBNP), cardiogenic death and heart failure (HF) readmission. Statistical analysis includes Kaplan-Meier analysis and Cox regression which are used to explore the relationship between SMI and outcome events.

resultsA total of 1,211 eligible CHF patients were involved and finally 1,047 patients were followed up successfully. After treatment, the cases of NYHA classification decline in the exposed and non-exposed groups accounted for 64.30% and 43.45%, respectively; the improvement values of LVEF were 8.89% and 7.91%, respectively; the improvement values of NT-ProBNP were 909 pg/mL and 735 pg/mL, respectively. After exposure on SMI, the rates of cardiogenic death and HF readmission reduced from 15.43% to 10.18% and 38.93% to 32.37%. According to Kaplan-Meier analysis, the log-rank P value of SMI and cardiogenic death was 0.014, while the counterpart of SMI and HF readmission was 0.025. Cox regression analysis indicated that for cardiogenic death, age, cardiomyopathy, diabetes, and NYHA classification were risk factors while β-blockers, aldosterone receptor antagonists, Chinese patent medicine/decoction and SMI were protective factors. Likewise, for HF readmission, age, cardiomyopathy, and NYHA classification were risk factors while SMI was a protective factor.

conclusionCombination with SMI on the standardized Western medicine treatment can effectively reduce cardiogenic mortality and readmission rate in CHF patients, and thereby improve the long-term prognosis.

Indexed as

Heart FailureVentricular Function, LeftBiomarkersDrug CombinationsDrugs, Chinese HerbalFollow-Up StudiesHumansNatriuretic Peptide, BrainPeptide FragmentsPrognosisRetrospective StudiesStroke VolumeBiomarkersDrug CombinationsDrugs, Chinese Herbalfructus schizandrae, radix ginseng, radix ophiopogonis drug combinationNatriuretic Peptide, BrainPeptide Fragmentschronic heart failurecohort studylong-term prognosisoutcome eventsShenmai Injection

Identifiers

PMID34874517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.